title: Hepatitis C-associated hepatocellular carcinoma.
abstract: In the United States, a large percentage of patients with hepatocellular carcinoma are serologically negative for hepatitis B. We conducted a retrospective study to determine the prevalence of hepatitis C antibody in the sera of 59 patients with hepatocellular carcinoma who were HBsAg-negative and had no evidence of alcoholic liver disease, primary biliary cirrhosis, autoimmune hepatitis, hemochromatosis or alpha 1-antitrypsin deficiency. Twenty patients (34%) were hepatitis C antibody-positive and hepatitis B core antibody-negative. All twenty patients had underlying cirrhosis, and seven (35%) had histories of transfusions. Eleven (19%) additional patients were also hepatitis C antibody-positive but were hepatitis B core antibody-positive as well. Twenty-one (36%) patients were both hepatitis C antibody- and hepatitis B core antibody-negative and seven (12%) were hepatitis C antibody-negative but hepatitis B core antibody-positive. The prevalence of hepatitis C antibody was also determined among three other population groups serving as controls and found to be 14% in 28 HbsAg-positive patients with hepatocellular carcinoma, 44% in 76 patients with cryptogenic cirrhosis and 0.5% in 200 consecutive volunteer blood donors. We conclude that hepatitis C antibody is prevalent among patients with hepatocellular carcinoma and may therefore be a common causative agent of this disease. A significant number of patients with and without cirrhosis, negative for hepatitis C antibody and hepatitis B core antibody, remain without a discernible cause for this malignancy. Perhaps a second- or third-generation test will detect hepatitis C antibody in some of these patients.
authors.affiliation: Division of Hepatology, University of Miami School of Medicine.
authors.forename: F
authors.initials: F
authors.lastname: Hasan
authors.forename: L J
authors.initials: LJ
authors.lastname: Jeffers
authors.forename: M
authors.initials: M
authors.lastname: De Medina
authors.forename: K R
authors.initials: KR
authors.lastname: Reddy
authors.forename: T
authors.initials: T
authors.lastname: Parker
authors.forename: E R
authors.initials: ER
authors.lastname: Schiff
authors.forename: M
authors.initials: M
authors.lastname: Houghton
authors.forename: Q L
authors.initials: QL
authors.lastname: Choo
authors.forename: G
authors.initials: G
authors.lastname: Kuo
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D005431:Florida / Q000453:epidemiology; D006508:Hepatitis Antibodies / Q000097:blood; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology / Q000276:immunology; D006518:Hepatitis Viruses / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D015995:Prevalence; D012189:Retrospective Studies; D016036:Seroepidemiologic Studies
chemical_list: D006508:Hepatitis Antibodies; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens